GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » Other Current Assets

Inhibitor Therapeutics (Inhibitor Therapeutics) Other Current Assets : $0.11 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics Other Current Assets?

Inhibitor Therapeutics's other current assets for the quarter that ended in Mar. 2024 was $0.11 Mil.

Inhibitor Therapeutics's quarterly other current assets increased from Sep. 2023 ($0.07 Mil) to Dec. 2023 ($0.11 Mil) and increased from Dec. 2023 ($0.11 Mil) to Mar. 2024 ($0.11Mil).

Inhibitor Therapeutics's annual other current assets declined from Dec. 2021 ($0.03 Mil) to Dec. 2022 ($0.02 Mil) increased from Dec. 2022 ($0.02 Mil) to Dec. 2023 ($0.11 Mil).


Inhibitor Therapeutics Other Current Assets Historical Data

The historical data trend for Inhibitor Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics Other Current Assets Chart

Inhibitor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 0.03 0.02 0.11

Inhibitor Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.07 0.11 0.11

Inhibitor Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Inhibitor Therapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
900 West Platt Street, Suite 200, Tampa, FL, USA, 33606-2173
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Executives
Black Robe Capital Llc 10 percent owner 900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii 10 percent owner 1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman director, 10 percent owner 1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii 10 percent owner C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc 10 percent owner 12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez director 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty 10 percent owner, officer: See Remarks C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara officer: CFO and Treasurer 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie director 4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin director C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab director, officer: Chairman of the Board C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606